Table 1.
The characteristics of included randomized controlled trials (RCTs).
| Authors (Ref) | Publication year | Country | Intervention/control (sample size) |
Duration (week) |
Dosage (mg/day) | Patients | Type of intervention | Mean age (control/intervention) |
|---|---|---|---|---|---|---|---|---|
| Adab et al. (2013) | 2013 | Iran | 39/36 | 8 | 2,100 mg of turmeric powder daily | Hyperlipidemic patients with type 2 diabetes mellitus | Turmeric powder | 55.66 ± 8.64, 54.76 ± 6.00 |
| Amin et al. (2015) | 2015 | Pakistan | 63/63 | 8 | 2.4 g/day (800 mg in three capsule) |
Metabolic syndrome | Powdered rhizome of Curcuma longa (turmeric) | 41.57 ± 12.8, 42.4 ± 13.7 |
| Chuengsamarn et al. (2014) | 2014 | Thailand | 107/106 | 24 | Curcuminoid content of 250 mg (six capsules daily) | Type 2 diabetes mellitus | Curcumin capsule (rhizomes of turmeric) | 59.58 ± 10.70, 59.16 ± 10.96 |
| Chuengsamarn et al. (2012) | 2012 | Thailand | 117/117 | 36 | Curcuminoid content of 250 mg (six capsules daily) | Type 2 diabetes mellitus | Dried rhizomes of turmeric (Curcuma longa Linn). | 57.93 ± 12.76, 56.95 ± 11.89 |
| Di Pierro et al. (2015) | 2015 | Italy | 22/22 | 8 | 800 mg/daily | Metabolic syndrome (overweight) | Curcumin-based product-Curcuma longa extract | 41.85 ± 15.91, 39.10 ± 16.8 |
| Ismail et al. (2016) | 2016 | Egypt | 15/14 | 4 | One capsule containing 500 mg curcumin | Pediatrics obese subjects | Curcuminoids are extracted from turmeric (Curcuma longa root) | 14.7 ± 4.52 |
| Ismail et al. (2016) | 2016 | Egypt | 15/14 | 4 | One capsule containing 500 mg curcumin | Adults obese subjects | Curcuminoids are extracted from turmeric (Curcuma longa root) | 37.55 ± 9.93 |
| Ismail et al. (2014) | 2014 | Egypt | 14/11 | 4 | One capsule containing 500 mg curcumin | Obese children | Curcuminoids are extracted from turmeric (Curcuma longa root) | 15.57 ± 5.79, 16.53 ± 8.7 |
| Kocher et al. (2016) | 2016 | Germany | 42/42 | 6 | 294 mg curcuminoids per day (as micelles) | Hyperlipidemic individuals (overweight) | Curcumin powder | 51.19 ± 17.61 |
| Mohammadi et al. (2017) | 2017 | Iran | 36/36 | 6 | 200 mg pure curcumin per day | Metabolic syndrome | Curcumin capsule | 38.59 ± 10.28, 37.52 ± 9.47 |
| Mohammadi et al. (2013) | 2013 | Iran | 15/15 | 4 | 500 mg C3 capsules containing 500 mg (1,000 mg/day) | Obese patients | Curcuminoids plus 5 mg BioPerine | 37.9 ± 12.7, 39.0 ± 9.0 |
| Nieman et al. (2012) | 2012 | USA | 30/30 | 4 | TM (2.8 g/day) or ∼112 mg curcumin | Overweight females | Turmeric capsule | 55.7 ± 1.4 |
| Panahi et al. (2017b) | 2017 | Iran | 44/43 | 8 | 500 mg C3 capsules containing 500 mg (1,000 mg/day) | Non-alcoholic fatty liver disease | Curcumin capsule (phytosomal form) | 47.21 ± 10.29, 44.98 ± 12.59 |
| Panahi et al. (2017a) | 2017 | Iran | 50/50 | 8 | 500 mg C3 capsules containing 500 mg (1,000 mg/day) | Type 2 diabetes mellitus | Curcuminoids plus 5 mg bioperine | 41 ± 7, 43 ± 8 |
| Panahi et al. (2016) | 2016 | Iran | 50/50 | 8 | 500 mg C3 capsules containing 500 mg (1,000 mg/day) | Metabolic syndrome | Curcuminoids plus 5 mg bioperine | 43.46 ± 9.70, 44.80 ± 8.67 |
| Rahimi et al. (2016) | 2016 | Iran | 35/35 | 12 | 80 mg/day | Type 2 diabetes mellitus | Nano-curcumin | 60.95 ± 10.77, 56.34 ± 11.17 |
| Rahmani et al. (2016) | 2016 | Iran | 37/40 | 8 | 500 mg/day | Non-alcoholic fatty liver disease | Curcumin powder | 48.95 ± 9.78, 46.37 ± 11.57 |
| Sahebkar et al. (2013) | 2013 | Iran | 15/15 | 4 | 500 mg C3 capsules containing 500 mg (1,000 mg/day) | Obese individuals | Curcuminoids plus 5 mg bioperine | 38.43 ± 10.84 |
| Yang et al. (2014) | 2014 | Taiwan | 30/29 | 12 | Curcumin extract capsule (630 mg three times daily) turmeric (C. longa) extract | Metabolic syndrome (overweight) | Curcumin capsule | 59.61 ± 14.09, 59.03 ± 10.10 |
TM, tumeric.